Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results
Authors
Discussion
Loading...
Member takes
Overview
Key Points
Key points are not available for this paper at this time.
Cite This Study
Kantarjian et al. (2023) studied this question.